Clinical Trials Logo

Seizures clinical trials

View clinical trials related to Seizures.

Filter by:

NCT ID: NCT06108778 Not yet recruiting - Clinical trials for Neonatal Convulsions

Incidence of Metabolic Disorders in Neonatal Convulsions

Start date: November 25, 2023
Phase:
Study type: Observational

Describe the incidence of metabolic disorders in neonatal convulsions affecting neonates at NICU Describe types of metabolic disorders causing neonatal convulsions

NCT ID: NCT06106425 Not yet recruiting - EEC Clinical Trials

Diagnostic and Prognostic Criteria of EEG in Neonatal Convulsions at Assiut University Children Hospital

Start date: October 2023
Phase:
Study type: Observational

Diagnostic and prognostic criteria of EEG in neonatal convulsions at Assiut University Children Hospital

NCT ID: NCT06045676 Not yet recruiting - Seizures Clinical Trials

Electrocardiographic Changes Among Epileptic and Non Epileptic Seizures in Children at Sohag University Hospital

Start date: September 25, 2023
Phase:
Study type: Observational

Epilepsy is a chronic disease triggered by increased impulsiveness of nerve cells in the brain and may require a lifelong treatment. Epilepsy is confirmed by two or more unprovoked seizures in more than 24 hours. Febrile Convulsion is another type of seizure occurring due to fever over 38 °C without a history of convulsion, CNS infection, electrolyte imbalance, metabolic disorder, intoxication, and trauma. Unlike epileptic seizures, there are non-epileptic seizures such as Breath Holding Spells that affect children's behaviors and often look like epileptic seizures. QT parameters elongation show the danger of dysrhythmia and unexpected sicknesses such as cardiomyopathy, mitral valve prolapse, ischemic coronary illness, and kidney disorders. Many investigators have reported changes in QT parameters in various diseases such as diabetes mellitus, celiac disease, thalassemia , epilepsy ,Breath holding spells and febrile seizure.

NCT ID: NCT06028945 Not yet recruiting - Epilepsy Clinical Trials

Evaluating the Impact of Virtual Reality Exposure Therapy on Epilepsy/Seizure-Specific Interictal Anxiety

AnxEMU
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this randomized control trial is to evaluate the impact of Virtual Reality (VR) Exposure Therapy (ET) on people with epilepsy who experience epilepsy/seizure-specific (ES) interictal anxiety. The main questions it aims to answer are: 1. Can virtual reality exposure therapy (VR-ET) help reduce ES-interictal anxiety in this population? 2. Are the study procedures sufficiently simple for participants to follow? Study Design Summary: - Fourteen (14) participants will be randomized into either an Experimental arm (receiving VR-ET) or Control arm - Participants will be expected to have VR-ET twice a day (5 min/session) for up to 10 days - Participants will complete self-reported questionnaires about anxiety, depression, quality life, and avoidance behaviours at baseline (T0), after completing their VR program (T2), and at a one-month follow-up (T3). - Participants will have a short interview with a researcher after completing their VR program (T2) as well as at a one-month follow-up (T3). Researchers will attempt to answer the study questions based on outcome measures taken at various timepoints and qualitative feedback from interviews.

NCT ID: NCT05947006 Not yet recruiting - Febrile Seizure Clinical Trials

Study of the Impact of a Pediatric Nurse's Consultation on Parental Anxiety During a Febrile Convulsion in Children

CONSULFE
Start date: July 13, 2023
Phase: N/A
Study type: Interventional

Febrile seizures are considered a very common syndrome presented in the pediatric emergency room. Witnessing these seizures may can cause anxiety in parents and generate them psychological sequelae such as major depressive disorder in the short term, or sleep disorders in the long term. An appropriate care for parents must be put in place in the emergency department, with the objective of improving their knowledge of this pathology and its care, and thus to reduce their anxiety and prevent potential inappropriate or even deleterious behavior and maneuvers towards the child.

NCT ID: NCT05944692 Not yet recruiting - Epilepsy Clinical Trials

Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)

Start date: May 6, 2024
Phase:
Study type: Observational [Patient Registry]

Concurrent electroencephalography (EEG) and new tripolar EEG (tEEG) will be recorded from adult and pediatric patients. In some patients stereo EEG (sEEG) will also be recorded concurrently.

NCT ID: NCT05897658 Not yet recruiting - Brain Tumor Clinical Trials

Levetiracetam Prophylaxis in Brain Tumor Resection Pilot

LeviTaTe Pilot
Start date: June 2024
Phase: Phase 3
Study type: Interventional

This study aims to evaluate feasibility of a double-blind randomized controlled trial for levetiracetam prophylaxis for prevention of seizure in the perioperative phase of brain tumor resection.

NCT ID: NCT05865561 Not yet recruiting - Epilepsy Clinical Trials

Identification of Volatile Organic Compounds (VOCs) as Biopredictors of Epileptic Seizures

ICONE
Start date: February 2024
Phase:
Study type: Observational

The unpredictable nature of epileptic seizures places people with epilepsy under permanent psychological stress, which contributes significantly to a restriction in their quality of life. The possibility of predicting the arrival of epileptic seizures would allow, in addition to taking a preventive treatment if the risk of seizure is close, to prevent traumas and accidents linked to possible falls during seizures, to authorize driving for certain people with epilepsy and to reduce the costs of medical care. To date and to our knowledge, no seizure detection device has been commercialized. There are commercialized devices based on biometric sensors other than EEG, but these are strictly dedicated to the detection of seizures and do not allow the anticipation of seizures. Regarding prediction, current research seems to have difficulties in developing convincing algorithms. The only system used successfully in real time would require a device implantable in the brain, but this would raise problems of acceptability. In addition, 20% of people with drug-resistant epilepsy have psychogenic non-epileptic seizures (PNES). These are sometimes difficult to differentiate from epileptic seizures by people with epilepsy and their caregivers, and their management differs from that of epileptic seizures. The distinction between these 2 types of events should also be taken into account by these prediction/detection tools. From the field of biomedical detection dogs, there is currently a converging body of evidence supporting that people with epilepsy emit specific odors associated with seizure events. Trained dogs have been shown to be able to discriminate body odors sampled during or just after an epileptic seizure from those sampled from the same subjects in various contexts outside of a seizure. It was also shown that a seizure can also be predicted by the volatile organic compounds (VOCs) released by the patient (human volatilome); the olfactory signature being already detectable up to 3h before a seizure. Another study used trained dogs to confirm that they are able to detect a seizure by smell and that this olfactory difference is already detectable before a seizure. The human volatilome VOCs lead is particularly promising, notably for its non-invasiveness and for the pre-ictal precocity that prediction allows. But at the moment, the studies are too studies are too preliminary, with sample sizes too small to conclude on the inter-individual generalization of the odor, taking into account the type of seizure involved and the influence of other variables (e.g., gender, age, medications). Moreover, in order to develop a reliable and transportable electronic detection tool, the identification of the VOCs involved is necessary, since the choice of sensors (e.g., to constitute an electronic nose) depends on it. The objective of this study is to overcome these shortcomings, by aiming at the identification of the informative odor(s) associated with epileptic events during the pre-ictal, ictal and post-ictal periods, taking into account the type of seizures (focal seizures, secondary generalized focal seizures, primary generalized seizures - motor and non-motor) and the inter-individual differences.

NCT ID: NCT05860153 Not yet recruiting - Febrile Convulsion Clinical Trials

Intermittent Levetricetam in Treatment of Febrile Convulsions

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The American Academy of Pediatrics (AAP) in 2011 published a clinical practice guideline defining a febrile seizure as "a seizure accompanied by fever (temperature ≥ 100.4°F or 38°C by any method), without central nervous system infection, that occurs in infants and children 6 through 60 months of age." Febrile seizures are further classified as simple (generalized in onset, last less than 15 minutes, and do not occur more than once in 24 hours.) or complex (FS duration longer than 15 min, repeated convulsions within the same day, and focal seizure activity or focal findings during the postictal period.).

NCT ID: NCT05649891 Not yet recruiting - Pneumonia Clinical Trials

Checklists Resuscitation Emergency Department

Start date: September 2023
Phase: N/A
Study type: Interventional

The study will systematically evaluate how an emergency manual-a collection of checklists and fact sheets-affects the performance of resuscitation teams during the management of priority one patients in an emergency department.